Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 5, 2001, Pages 496-499

  Safran, Howard ^a,b   Steinhoff, Margaret ^a   Mangray, Shamlal ^a   Rathore, Ritesh ^a   King, Thomas Charles ^a   Chai, Li ^a   Berzein, Katya ^a   Moore, Todd ^a   Iannitti, David ^a   Reiss, Philip ^a   Pasquariello, Terese ^a   Akerman, Paul ^a   Quirk, Daniel ^a   Mass, Robert ^a   Goldstein, Lisa ^a   Tantravahi, Umadevi ^a  

^a Brown University Oncology Group   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

HER 2 neu; Pancreatic cancer; Trastuzumab

Indexed keywords

TRASTUZUMAB;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE FREQUENCY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PANCREAS ADENOCARCINOMA; PREDICTION; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTOR, ERBB-2;

EID: 0034793404     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200110000-00016     Document Type: Article

References (25)

1. Cancer statistics
2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer-a randomized trial
3. Tumor suppressive pathways in pancreatic cancer
4. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
5. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
6. Studies of the HER-2 proto-oncogene in human breast and ovarian cancer
7. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of c-erbB-2 protein overexpression in primary breast cancer
8. c-erbB2 expression and response to adjuvant therapy in women with node-positive early breast cancer
9. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
10. Humanization of an anti-p185HER2 antibody for human cancer therapy
11. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
12. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
13. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial
14. Overexpression of HER-2/neu oncogene in human pancreatic carcinoma
15. The c-erbB-2 protooncogene in human pancreatic cancer
16. An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucinhypersecreting neoplasms and in ductal cell carcinomas of the pancreas
17. Overexpression of HER-2/neu oncogene in pancreatic cancer correlates with shortened survival
18. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms
19. Relationship of family cancer history to the expression of p53, p21WAF-1, Her2/NEU, and K-ras mutation in pancreatic adenocarcinoma
20. Pancreatic cancer: The potential clinical relevance of alterations in growth factors and their receptors
21. Determination of HER-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in-situ hybridization
22. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
23. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
24. HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach
25. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma